Selected drugs that received regulatory approval in 2012. Source: BCIQ: BioCentury Online Intelligence
Company
Product
Indication
2012 approval
Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)
Juxtapid lomitapide
Homozygous familial hypercholesterolemia (hoFH)
U.S.
Affymax Inc. (NASDAQ:AFFY)/ Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)
Omontys peginesatide
Anemia in chronic kidney disease (CKD) patients who are on dialysis
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA)
Adasuve Staccato loxapine
Schizophrenia or bipolar disorder
Alimera Sciences Inc. (NASDAQ:ALIM)/ pSivida Corp. (NASDAQ:PSDV; ASX:PVA)
Iluvien fluocinolone acetonide
Chronic diabetic macular edema (DME)
Austria/ Portugal/U.K.
Almirall S.A. (Madrid:ALM)/Forest Laboratories Inc. (NYSE:FRX)/Menarini Group/Quintiles Transnational Corp.
Tudorza Pressai aclidinium bromide (Bretaris/Eklira Genuair - EU)
Chronic obstructive pulmonary disease (COPD)
EU/U.S.
Amarin Corp. plc (NASDAQ:AMRN)
Vascepa icosapent ethyl
Severe hypertriglyceridemia
Amylin Pharmaceuticals LLC/Bristol-Myers Squibb Co. (NYSE:BMY)/Alkermes plc(NASDAQ:ALKS)
Bydureon exenatide once weekly using Alkermes' drug delivery technology
Type II diabetes
Arena Pharmaceuticals Inc. (NASDAQ:ARNA)/ Eisai Co. Ltd. (Tokyo:4523; Osaka:4523)
Belviq lorcaserin
Chronic weight management
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)
Iclusig ponatinib
Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)
Astellas Pharma Inc. (Tokyo:4503)
Myrbetriq mirabegron
Overactive bladder
AstraZeneca plc (LSE:AZN; NYSE:AZN)/ Bristol-Myers Squibb Co. (NYSE:BMY)
Forxiga dapagliflozin
EU
Bayer AG (Xetra:BAYN)/Onyx Pharmaceuticals Inc. (NASDAQ:ONXX)
Stivarga regorafenib
Metastatic colorectal cancer (mCRC)
BioSante Pharmaceuticals Inc. (NASDAQ:BPAX)/ Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA)
Bio-T-Gel testosterone gel
Male hypogonadism
BTG plc (LSE:BGC)
Voraxaze glucarpidase
Lower toxic levels of chemotherapy drug methotrexate
Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC)
Pixuvri pixantrone
Non-Hodgkin's lymphoma (NHL)
EU (conditional)
Corcept Therapeutics Inc. (NASDAQ:CORT)
Korlym mifepristone
Cushing's syndrome
Discovery Laboratories Inc. (NASDAQ:DSCO)
Surfaxin lucinactant
Prevent respiratory distress syndrome in premature infants
EffRx Pharmaceuticals S.A./Mission Pharmacal Co./ Merck & Co. Inc. (NYSE:MRK)
Binosto alendronate
Osteoporosis
Eisai Co. Ltd. (Tokyo:4523; Osaka:4523)
Fycompa perampanel
Epilepsy
EU / U.S.
Eli Lilly and Co. (NYSE:LLY)
Amyvid florbetapir
Image beta amyloid neuritic plaque density in patients being evaluated for Alzheimer's disease (AD)
Exelixis Inc. (NASDAQ:EXEL)
Cometriq cabozantinib
Metastatic medullary thyroid cancer
Gedeon Richter Ltd. (Budapest:RICHTER)/ HRA Pharma S.A.
Esmya ulipristal acetate
Moderate to severe uterine fibroids
Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)
Perjeta pertuzumab
HER2-positive metastatic breast cancer
Switzerland/U.S.
Genentech Inc./Roche (SIX:ROG; OTCQX:RHHBY)/Curis Inc. (NASDAQ:CRIS)
Erivedge vismodegib
Advanced basal cell carcinoma (BCC)
Gilead Sciences Inc. (NASDAQ:GILD)/ Japan Tobacco Inc. (Tokyo:2914; Osaka:2914)
Stribild elvitegravir/cobicistat/ emtricitabine/tenofovir
HIV-1 infection
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)
Raxibacumab
Treat and prevent inhalational anthrax
Incyte Corp. (NASDAQ:INCY)/Novartis AG (NYSE:NVS; SIX:NOVN)
Jakafi ruxolitinib
Myelofibrosis
Canada/EU
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD)/ Almirall S.A. (Madrid:ALM)/Forest Laboratories Inc. (NYSE:FRX)
Linzess linaclotide (Constella - EU)
Chronic constipation and irritable bowel syndrome with constipation (IBS-C)
Johnson & Johnson (NYSE:JNJ)
Sirturo bedaquiline
Multi-drug resistant pulmonary tuberculosis (TB)
Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151)
Poteligeo mogamulizumab
CC chemokine receptor 4 (CCR4; CD194)-positive T cell leukemia- lymphoma
Japan
MedImmune LLC/AstraZeneca plc (LSE:AZN; NYSE:AZN)
FluMist Quadrivalent (MEDI-3250)
Prevent seasonal influenza
Medivation Inc. (NASDAQ:MDVN)/ Astellas Pharma Inc. (Tokyo:4503)
Xtandi enzalutamide
Metastatic castration-resistant prostate cancer (CRPC)
Merck & Co. Inc. (NYSE:MRK)
Zioptan tafluprost
Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508)/Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568)
Tenelia teneligliptin
Napo Pharmaceuticals Inc./Salix Pharmaceuticals Ltd. (NASDAQ:SLXP)
Fulyzaq crofelemer
Non-infectious diarrhea in HIV/AIDS patients on antiretroviral therapy
Novartis AG (NYSE:NVS; SIX:NOVN)
Signifor pasireotide
Cushing's disease
NPS Pharmaceuticals Inc. (NASDAQ:NPSP)/ Takeda Pharmaceutical Co. Ltd. (Tokyo:4502)
Gattex teduglutide (Revestive - EU)
Short bowel syndrome (SBS)
Onyx Pharmaceuticals Inc. (NASDAQ:ONXX)
Kyprolis carfilzomib
Multiple myeloma (MM)
Pfizer Inc. (NYSE:PFE)
Xeljanz tofacitinib
Moderate to severe rheumatoid arthritis (RA)
Inlyta axitinib
Advanced renal cell carcinoma (RCC)
Bosulif bosutinib
Chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) CML
Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY)
Bronchitol mannitol
Cystic fibrosis (CF)
Protalix Biotherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX)/Pfizer Inc. (NYSE:PFE)
Elelyso taliglucerase alfa
Type I Gaucher's disease
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)/ Sanofi (Euronext:SAN; NYSE:SNY)
Zaltrap ziv-aflibercept
mCRC
Sanofi (Euronext:SAN; NYSE:SNY)
Aubagio teriflunomide
Relapsing forms of multiple sclerosis (MS)
Sosei Group Corp. (Tokyo:4565)/ Vectura Group plc (LSE:VEC)/Novartis AG (NYSE:NVS; SIX:NOVN)
Seebri glycopyrronium bromide (NVA237)
COPD
EU/Japan
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)
Trokendi XR topiramate
U.S. (tentative)
Oxtellar XR oxcarbazepine
Talon Therapeutics Inc. (OTCBB:TLON)/ Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR)
Marqibo vincristine
Philadelphia chromosome-negative ALL
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)
Synribo omacetaxine mepesuccinate
Chronic or accelerated phase CML
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)
Kalydeco ivacaftor
CF patients with at least one copy of the G551D mutation in the CF transmembrane conductance regulator (CFTR) gene
Vivus Inc. (NASDAQ:VVUS)
Qsymia phentermine/topiramate
Vivus Inc. (NASDAQ:VVUS)/Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508)
Stendra avanafil
Erectile dysfunction (ED)
If you are a current subscriber, log in below or in the upper right corner of this page.
UserID or email address
Password
Forgot password | Forgot Login
If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.
Purchase This Article for Individual Use :
Access this BioCentury on BioBusiness article Cover Story for your individual use via a permanent link that allows you to read or print the article, and any sub-articles, charts, tables and/or graphs related to this specific story: $150. The article link will be posted on the purchase transaction web page, and also emailed to you with your purchase confirmation.
Purchase This Article for Limited One-Time Distribution and Posting to Your Website :
Receive a formatted PDF reprint of this article, including any sub-articles, charts, tables and/or graphs related to this specific article, with rights for limited one-time redistribution and posting to your website: $750. Please allow 24-48 hours for delivery.
Whether you want an individual subscription or need a global group license, we have the products, the experience and the customer support that biopharma executives, researchers, investors, service providers, and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Get a 4-week free trial subscription to see the important articles you are missing.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
Email to Colleague
Type the code from the image